Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6152W HIGH $23.00
Volume
5.76 K
Value Traded
24.17 K
Short % Float
8.73%
Days to Cover
3.5
-4.55%Week
-17.81%1 Month
-41.04%3 Month
-57.84%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.52 M
EPS (TTM)
-1.46
P/E Ratio
-
Ent. Value
24.67 M
Total Shares
5.93 M
Float Shares
1.73 M
Insiders
71.19%
Institutions
21.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ONMD Catalyst Timeline
Dated clinical, regulatory and corporate events for OneMedNet Corp Class A Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for OneMedNet Corp Class A Common Stock
49Total events
2Upcoming
15Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 44
▲Partnership / LicenseCorporate
OneMedNet signs 12th channel partner agreement with global pharmaceutical intelligence provider
▲Partnership / LicenseCorporate
OneMedNet adds leading hospital system to iRWD platform and federated provider network
▲Partnership / LicenseCorporate
OneMedNet signs Mediplexus as 11th channel partner for RWD distribution in Korea
▲Partnership / LicenseCorporate
OneMedNet signs seven-figure multiyear RWD licensing agreement with AI precision medicine company
▲Partnership / LicenseCorporate
OneMedNet enters multi-year resale agreement with Atropos Health
▲Quarterly UpdateCorporate
OneMedNet reports year-to-date bookings of approximately $16.2 million, a 16X increase versus same period 2025
▲Partnership / LicenseCorporate
New agreement to deliver clinical RWD to AI-driven drug development company
▲Partnership / LicenseCorporate
Agreement to supply regulatory-grade RWD for foundational AI model development
◆Quarterly UpdateCorporate
Expects to recognize substantially all bookings as revenue by end of Q3 2026
▲Quarterly UpdateCorporate
Secured over $3 million in new bookings year-to-date 2026, surpassing full-year 2025 bookings
▲Enrollment MilestoneTrial
OneMedNet iRWD Network surpasses 90 million patient journeys and 270 million studies
▲Product LaunchPost-Market
Next phase of commercial launch with RWD Platform powered by Palantir Foundry
▲Partnership / LicenseCorporate
OneMedNet partners with ViuHealth to expand autoimmune dataset scale
autoimmune diseasessource ↗
▲Partnership / LicenseCorporate
OneMedNet announces strategic neuro data partnership with Risorius
▲Quarterly UpdateCorporate
Delivered anonymized RWD feed of 1.5M patients and 4M encounters to a premier healthcare data and analytics organization
▲Quarterly UpdateCorporate
Successful demonstration of live feeds, subscription access, and AI-driven search at major tradeshows
▲Quarterly UpdateCorporate
Record 2025 bookings of $2.79 million, surpassing prior year by more than 4.1X
◆Quarterly UpdateCorporate
Deadline to file delinquent Form 10-Qs (Q1 and Q2 2024) extended to December 11, 2024
▼Equity OfferingCorporate
Private placement of common stock and pre-funded warrants for $4.6 million gross proceeds
▼Debt Royalty FinancingCorporate
Received $1.5M advance under convertible promissory note from Yorkville
▼Equity OfferingCorporate
Entered into standby equity purchase agreement with Yorkville for up to $25M
●Quarterly UpdateCorporate
Extended deadline to complete business combination to May 11, 2024
●Management ChangeCorporate
Aaron Green assumes role of President and CEO; Paul Casey retires and shifts to advisory role
▲FDA Filing AcceptedRegulatory Filing
SEC declares effective Registration Statement on Form S-4 for business combination
▲Quarterly UpdateCorporate
Stockholders approved charter and trust agreement amendments to extend business combination deadline
◆AcquisitionCorporate
Data Knights Acquisition Corp. extends period to consummate initial business combination with OneMedNet to August 11, 2022
◆AcquisitionCorporate
OneMedNet files S-4 registration statement for business combination with Data Knights Acquisition Corp.
Past FDA Catalysts and PDUFA Decisions
How ONMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ONMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yu JeffreyDirector, Officer (Chief Medical Officer), 10% Owner | BuyOffering | 45,126 896,840 held | $5.54 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ONMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ONMD for Q2 2026. | ||||
Ownership Trends
ONMD Short Interest
Shares sold short, counted twice a month.
8.73%
Short % of Float
of tradable shares sold short
151.0K
Shares Sold Short
+33.0% vs prior count
3.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
43.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ONMD ranks across every disease it competes in
Competitive Position is a premium feature
See how ONMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialONMD News
-ONMD
Nov 3, 2026▲ +0.6%today
OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement Announced September 30
OneMedNet Corporation announced a high six-figure add-on order under a multiyear agreement, increasing data volume by 150%. This order, received shortly after the initial agreement on September 30, reflects the customer's need for more data to enhance its derivative data offering. The company emphasizes its rapid delivery and high-quality data as key factors for customer retention.
Read more →-ONMD
Oct 19, 2026OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
OneMedNet Corporation has signed its 12th channel partner agreement with a global provider of pharmaceutical intelligence. This partnership will allow the distribution of OneMedNet's high-quality, de-identified clinical data to pharmaceutical customers worldwide. The agreement aims to enhance OneMedNet's presence in the rapidly growing Real-World Data market, which is expected to reach $7.1 billion by 2033.
Read more →-ONMD
Oct 15, 2026OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals
OneMedNet Corporation has announced the addition of a leading hospital system to its iRWD platform, which will expand its network by up to 12 hospitals. This partnership enhances the scale and clinical depth of OneMedNet's healthcare data network. The expansion aims to support AI innovation and the generation of Real-World Evidence for regulatory submissions and clinical research.
Read more →-ONMD
Oct 7, 2026OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region
OneMedNet Corporation has signed a channel partner agreement with Mediplexus, marking its 11th partnership. This collaboration will enable OneMedNet to supply U.S.-sourced Real World Data to Mediplexus, enhancing its presence in Korea and the Asia Pacific region. The partnership aims to support local biopharma and medical AI companies in global clinical trials and drug development.
Read more →-ONMD
Sep 30, 2026▲ +11%on this news
OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution
OneMedNet Corporation has announced a significant seven-figure multiyear agreement to provide de-identified, multimodal, longitudinal clinical Real World Data to an AI-enabled precision medicine company. The data will enhance the customer's capabilities in training clinical models and creating a licensable dataset. This partnership is expected to generate recurring sublicensing revenue for OneMedNet.
Read more →-ONMD
Sep 25, 2026▼ -8.4%on this news· ran to -18% by day 3shared move
OneMedNet Corporation Announces 1-for-10 Reverse Stock Split
OneMedNet Corporation announced a 1-for-10 reverse stock split effective September 29, 2026, after receiving stockholder approval. This move aims to ensure compliance with Nasdaq's minimum bid price requirements and to attract more investors. The number of outstanding shares will decrease from approximately 59 million to about 5.9 million, while the total authorized shares will remain unchanged.
Read more →-ONMD
Sep 22, 2026Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development
Atropos Health has announced a significant expansion of its federated Atropos Evidence Network. This expansion includes collaborations with Norstella and Arcadia, as well as new partnerships with OneMedNet Corporation. The aim is to enhance the scope of real-world evidence generation and improve clinical decision support and AI model development.
Read more →-ONMD
Sep 22, 2026▼ -5.5%on this newsshared move
OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health
OneMedNet Corporation has entered a multi-year partnership with Atropos Health to integrate its regulatory decision-grade Real-World Data into Atropos' platform. This collaboration aims to enhance the quality of real-world evidence available to health systems and researchers. The agreement is structured as a subscription-based license, ensuring continuous data access and revenue growth for OneMedNet.
Read more →-ONMD
Sep 18, 2026▲ +14.6%on this newsshared move
OneMedNet Reports Record Bookings as Faster Fulfillment Begins
OneMedNet Corporation reported a significant increase in year-to-date bookings, reaching approximately $16.2 million, which is a 16-fold increase compared to the previous year. The company has improved its order fulfillment speed by 50 times, allowing for quicker delivery of data services. Approximately half of the new contracts are from new customers, indicating strong market demand.
Read more →-ONMD
Aug 31, 2026OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company
OneMedNet Corporation has announced a new agreement to provide de-identified, high-quality clinical Real-World Data to an AI-driven drug development company. Their iRWD™ Platform enables rapid feasibility assessments and data delivery, supporting the development of AI models for new therapies. The agreement highlights the increasing demand for reliable healthcare data sourced directly from providers.
Read more →-ONMD
Jul 28, 2026▲ +17%on this news
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
OneMedNet Corporation has announced an agreement valued at over $11.5 million to supply regulatory-grade Real-World Data for AI model development. The company will provide high-quality, de-identified healthcare data, enhancing its capabilities in delivering essential data for foundational AI innovations. This agreement is expected to strengthen OneMedNet's commercial momentum and expand its extensive network.
Read more →-ONMD
Jun 10, 2026▼ -7.1%on this news
OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025
OneMedNet Corporation has announced over $3 million in new bookings for 2026, surpassing its total bookings for the entirety of 2025. The company anticipates recognizing most of these bookings as revenue by the end of Q3 2026, reflecting strong demand for its AI-driven Real-World Data platform. This growth is attributed to new customer acquisitions and expanded engagements within the life sciences sector.
Read more →-ONMD
Jun 3, 2026OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
OneMedNet Corporation has announced significant milestones, surpassing 90 million patient journeys and 270 million studies in its iRWD™ Network. The company has expanded its healthcare partner network to over 2,300 sites, reflecting its commitment to enhancing Real-World Data availability. This growth aligns with OneMedNet's strategic priorities to create long-term value for shareholders.
Read more →-ONMD
Feb 27, 2026▲ +44.6%on this news
OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry
OneMedNet Corporation announced the next phase of its commercial launch for its Real-World Data (RWD) platform powered by Palantir Foundry. Following successful demonstrations, the company is converting customer evaluations into subscriptions, which are expected to drive significant recurring revenue. The platform offers unique real-time data access and enhanced analytical capabilities, benefiting life sciences and healthcare organizations.
Read more →-ONMD
Feb 26, 2026▲ +8.9%on this news· ran to +57% by day 1shared move
OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers
OneMedNet Corporation has partnered with ViuHealth to enhance its autoimmune dataset through the iRWD platform. This collaboration aims to provide comprehensive, longitudinal data that can accelerate drug discovery and support regulatory initiatives. The partnership is expected to bolster OneMedNet's subscription revenue strategy by integrating high-value data, benefiting both companies and their clients in the life sciences sector.
Read more →-ONMD
Feb 24, 2026OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
OneMedNet Corporation has entered a strategic data licensing agreement with Risorius Co., Ltd. to enhance EEG-based digital biomarkers for CNS indications. The partnership allows Risorius access to large-scale EEG and PSG data, supporting their R&D and AI platform development. The swift execution of the agreement highlights the strong alignment between the two companies and the growing demand for high-quality datasets in the neurotechnology field.
Read more →-ONMD
Feb 12, 2026▲ +18.3%on this news
OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition
OneMedNet reported record 2025 bookings of $2.79 million. This amount exceeds the prior year by more than four times. The company is shifting its business model toward recurring subscription agreements. This transition aims to increase deal sizes and provide more predictable revenue streams for the fiscal year 2026.
Read more →-ONMD
Jan 22, 2026▲ +12.1%on this newsshared move
OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software
OneMedNet Corporation announced that its Real-World Data supported mlHealth 360 in obtaining FDA 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software for detecting intracranial hemorrhage. The software analyzes CT images in about 6 seconds, facilitating quicker clinical decisions. This achievement underscores OneMedNet's role as a leading provider of regulatory-grade data in the healthcare AI sector.
Read more →-ONMD
Jan 16, 2026▲ +5.9%on this newsshared move
OneMedNet Delivers a Real-World Data feed of 1.5M Patients consisting of 4M encounters
OneMedNet Corporation has delivered a significant Real-World Data feed of 1.5 million patients and 4 million encounters to a healthcare analytics organization. This dataset supports enterprise-scale testing and confirms the recipient's platform's ability to manage complex healthcare data. The delivery reinforces OneMedNet's subscription model, enhancing predictable revenue streams and partnerships in the healthcare data market.
Read more →-ONMD
Dec 30, 2024▲ +9.8%on this news
OneMedNet Regains Compliance with NASDAQ Periodic Filing Requirements MINNEAPOLIS
OneMedNet Corporation has announced that it has regained compliance with NASDAQ's periodic filing requirements after submitting its financial reports for the first three quarters of 2024. The company appointed new leadership, including an interim CFO, to enhance its financial reporting processes and has raised over $6.4 million in private placements to improve liquidity. Additionally, OneMedNet is focusing on expanding its presence in the Real World Data market through strategic initiatives and partnerships, including an agreement with Bayer's AI Innovation Platform.
Read more →About OneMedNet Corp Class A Common Stock
HeadquartersTRIDENT COURT, 1 OAKCROFT ROAD, SURREY, X0, KT9 1BD
BIOPHARMAWATCH ELITE PLUS
Trade the next ONMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime